Neutralizing antibody for epstein barr virus-associated disease
Described herein are compositions, methods, and uses relating to an EBV-neutralizing antibody.
1. A composition comprising a purified, recombinant, humanized EBV-neutralizing antibody, wherein the antibody comprises the following CDRs:
CDR H1,
GSSFTDYT;
(SEQ ID NO: 5)
CDR H2,
INPYNGGT;
(SEQ ID NO: 6)
CDR H3,
AGGLRRVNWFAY;
(SEQ ID NO: 7)
CDR L1,
TGAVTTSNY;
(SEQ ID NO: 14)
CDR L2,
GTN;
(SEQ ID NO: 15)
and
CDR L3,
VLWHSNHWV.
(SEQ ID NO: 16)
2. The composition of claim 1 , wherein the antibody has a heavy chain variable region having the amino acids:
(SEQ ID NO: 1)
EVQLQQSGPELVKPGTSMKISCKASGSSFTDYTMNWMKQSHGKNLEWIGL
INPYNGGTRYNQKFKGKATLTLDKSSSTAYMEVLSLTSEDSAVYYCAGGL
RRVNWFAYWGQGTLVSVSA
and
and a variable light chain region having the amino acids:
(SEQ ID NO: 4)
QAVLTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLI
GGTNNRVPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCVLWHSNHWVF
GGGTKLTVL;
and said variable heavy and light chain regions are linked to human constant regions.
3. The composition of claim 1 , wherein the purified, recombinant, humanized EBV-neutralizing antibody comprises human variable chain framework regions and the following CDRs:
CDR H1,
GSSFTDYT;
(SEQ ID NO: 5)
CDR H2,
INPYNGGT;
(SEQ ID NO: 6)
CDR H3,
AGGLRRVNWFAY;
(SEQ ID NO: 7)
CDR L1,
TGAVTTSNY;
(SEQ ID NO: 14)
CDR L2,
GTN;
(SEQ ID NO: 15)
and
CDR L3,
VLWHSNHWV.
(SEQ ID NO: 16)
4. A method for treating infectious mononucleosis in a subject suffering from genetic immunodeficiency comprising administering to the subject a pharmaceutical composition comprising a purified, recombinant, humanized EBV-neutralizing antibody of claim 1 .
5. The method of claim 4 , wherein the purified, recombinant, humanized EBV-neutralizing antibody comprises the following CDRs:
CDR H1,
GSSFTDYT;
(SEQ ID NO: 5)
CDR H2,
INPYNGGT;
(SEQ ID NO: 6)
CDR H3,
AGGLRRVNWFAY;
(SEQ ID NO: 7)
CDR L1,
TGAVTTSNY;
(SEQ ID NO: 14)
CDR L2,
GTN;
(SEQ ID NO: 15)
and
CDR L3,
VLWHSNHWV;
(SEQ ID NO: 16)
wherein the CDRs are linked to human variable chain framework regions or human constant chain regions, or both of these.
6. A method of treating EBV-induced lymphoproliferative disease in immunosuppressed subjects, the method comprising administering to the subject a pharmaceutical composition comprising a purified, recombinant, humanized EBV-neutralizing antibody of claim 1 .